Time filter

Source Type

Nicolini F.E.,Departement dHematologie Clinique | Nicolini F.E.,French intergroup for CML Fi LMC group | Hayette S.,French National Center for Scientific Research | Hayette S.,French intergroup for CML Fi LMC group | And 21 more authors.
Leukemia Research | Year: 2011

This phase I/II study was designed to demonstrate the tolerance and the efficacy of a combination of pegylated interferon-α 2a to Imatinib mesylate (IM) 600mg daily in cytogenetically IM-resistant but in CHR chronic phase CML patients. The combination was generally well tolerated in the 15 evaluable patients. A significant reduction of the Ph1+ BM metaphases was observed in these poor prognosis patients, with 2 long-term CCyR including 2 MMR. After a median follow-up of 43 months, 93% of patients are alive. The addition of PegIFNα2a to IM600 is feasible, and able to overcome resistance within this context. © 2010 Elsevier Ltd.

Discover hidden collaborations